Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV
Debora Franceschini, … , Mario U. Mondelli, Vincenzo Barnaba
Debora Franceschini, … , Mario U. Mondelli, Vincenzo Barnaba
Published February 23, 2009
Citation Information: J Clin Invest. 2009;119(3):551-564. https://doi.org/10.1172/JCI36604.
View: Text | PDF
Research Article

PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV

  • Text
  • PDF
Abstract

CD4+CD25+Foxp3+ Tregs suppress autoimmune responses. In addition, they limit T cell responses during chronic infection, thereby minimizing T cell–dependent immunopathology. We sought to investigate how Tregs are regulated in the livers of patients chronically infected with HCV, where they control the balance between an adequate protective immune response and suppression of immunopathology. We found that, despite accumulating and proliferating at sites of infection in the livers of patients chronically infected with HCV, Tregs were relatively less expanded than CD4+CD25+Foxp3– effector T cells. The relative lower expansion of intrahepatic Tregs coincided with their upregulation of programmed death–1 (PD-1). PD-1 expression inversely correlated with both Treg proliferation and clinical markers of immune suppression in vivo. Consistent with the possibility that PD-1 controls Tregs, blockade of the interaction between PD-1 and programmed death–1 ligand 1 (PD-L1) enhanced the in vitro expansion and function of Tregs isolated from the livers of patients chronically infected with HCV. Blockade of the interaction between PD-L1 and B7.1 also improved the proliferation of these cells. Interestingly, both PD-1 and phosphorylated STAT-5 were overexpressed in intrahepatic Tregs in a parallel fashion in steady disease conditions, and in an alternate-fluctuating fashion during the course of severe hepatitis reactivation. Notably, PD-L1 blockade upregulated STAT-5 phosphorylation in Tregs ex vivo. These data suggest that PD-L1 negatively regulates Tregs at sites of chronic inflammation by controlling STAT-5 phosphorylation.

Authors

Debora Franceschini, Marino Paroli, Vittorio Francavilla, Melissa Videtta, Stefania Morrone, Giancarlo Labbadia, Antonella Cerino, Mario U. Mondelli, Vincenzo Barnaba

×

Figure 9

Improvement of pSTAT-5 upregulation in PD-1+ Tregs by PD-L1 blockade ex vivo.

Options: View larger image (or click on image) Download as PowerPoint
Improvement of pSTAT-5 upregulation in PD-1+ Tregs by PD-L1 blockade ex ...
(A) Single representative flow cytometry experiment of 6, in which HCV-IHLs were stimulated for 6 h with anti-CD3/CD28 and 50 U/ml IL-2 in the presence or absence of anti–PD-L1. Cells were then stained with the antibodies to the indicated molecules. Contour plot analyses are gated as indicated and show percentages of pSTAT-5+ cells. Counter plot analyses of samples stained with isotype control of anti–pSTAT-5 are shown above. The percentage of cells is indicated in each quadrant. pSTAT-5 MFI values are shown below the flow cytometry analyses. (B) Single representative flow cytometry experiment of 3, in which CD4+CD25+PD-1+ cells sorted from PBLs were stimulated or not for 6 h with anti-CD3/CD28 and 100 U/ml IL-2 in the presence or absence of anti–PD-L1. Cells were then stained with the antibodies to the indicated molecules. Contour plot analyses are gated on CD4+CD25+PD-1+ cells and show percentages of PD-1+pSTAT-5+ or Foxp3+pSTAT-5+ cells. The percentage of cells is indicated in each quadrant. pSTAT-5 MFI values are shown below the flow cytometry analyses.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts